Skip to content

ImmunoPrecise teams up with Zymeworks for COVID-19 antibody

September 17, 2020

ImmunoPrecise Antibodies (OTCQB:IPATF) announces a research collaboration with Zymeworks (NYSE:ZYME) giving the Company access to Zymeworks’ Azymetric and EFECT platforms for the further development of its multiple antibody candidates to fight COVID-19.

Under the terms of the agreement, IPA will transform its previously tested and potent SARS-CoV-2 neutralizing antibodies into bispecific and multispecific antibodies using the Zymeworks’ platforms.

These sets of candidates will be thoroughly tested using SARS-CoV-2 spike protein provided by the National Research Council Canada, prior to pre-clinical manufacturing for animal studies.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: